Green light given to £200m solar farm
Byers Gill Solar Farm, which will have several sites between Darlington and Stockton, has been granted a development consent order, which is required for nationally significant infrastructure projects.
Some residents had previously argued the development would devastate communities, dominate the landscape and diminish farmland.
Developer RWE has been approached for comment.
The 50MW farm, which will be made up of several blocks of development, will be located in Brafferton, Hauxley Farm, Byers Gill Wood, Great Stainton, and two near Bishopton.
RWE has said the development, which will cover about 490 hectares (1,211 acres) of land in total, will have a lifespan of 40 years after which it will be removed.
Bishopton resident Norman Mullaney previously said there were fears the solar farm could make people "prisoners" in the village.
"There is a large amount of anxiety and anguish about the impact of the poorly-located solar farm," he said. "The size of the development is a major concern."
In a document detailing its recommendation, the Planning Inspectorate said it had given "great weight" to the "residual significant adverse landscape and visual effects" that may be caused by the farm when considering the plans.
It said some of the plans would "alter" Bishopton's "unobstructed country view" to one that would be "dominated at points" by landscape screening, such as hedgerows.
It also said the developer would be providing a "community benefit fund" worth about £1.5m over the solar farm's lifespan, which would be spend on things such as electric vehicle charging points, rooftop solar panels and picnic benches.
The energy consumers minister Miatta Fahnbulleh said that approving the plans was "another step forward" in the government's mission to make the country a "clean energy superpower".
Follow BBC Tees on X, Facebook, Nextdoor and Instagram.
More stories from BBC North East and Cumbria
Giant solar farm plans set for public hearing
Campaigners step up opposition to solar farm
Related internet links
Byers Gill
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hedge fund tycoon Hosking says rival Telegraph bid "ready to go"
The hedge fund founder enlisted to back a bid for The Daily Telegraph says the offer is "ready to go" if a takeover of the broadsheet title involving sovereign Gulf money runs into further regulatory problems. Sky News has learnt that Jeremy Hosking, the prominent City figure who co-founded Marathon Asset Management, is pledging to inject £100m of his own money into the newspaper group if the self-styled 'British bid' of which he is part is successful. Mr Hosking, who now runs Hosking Partners, has been working with Dovid Efune, the owner of the New York Sun, in an effort to gain control of the Telegraph for several months. Money latest: They have been thwarted, though, by an agreement reached with RedBird Capital Partners, the US-based investment firm, to buy the titles for £500m following a two-year battle which has plunged the Telegraph into a protracted state of limbo. RedBird's bid includes tens of millions of pounds of funding from IMI, a state-backed Abu Dhabi vehicle, which cleared a key hurdle last week when the House of Lords voted against a 'fatal motion' which would have blocked the sovereign investment. The outcome of the vote was not without fierce debate, with 155 peers supporting the ban. IMI is controlled by Sheikh Mansour bin Zayed Al Nahyan, the vice-president of the United Arab Emirates and ultimate owner of Manchester City Football Club. Speaking through Mr Efune, Mr Hosking said in a statement on Wednesday morning: "We have been following the latest developments closely and with the best outcome for all Telegraph stakeholders front of mind. "We understand from the Lords debate last week that there is now a legal requirement for the government to formally investigate all the foreign government ties that may result in influence over the current preferred buyer. "Should the buyer be deemed unsuitable, our "British Bid" is ready to go. "We believe our current capitalization is more than adequate to replace the controlling shareholder's portion of the deal. "My own personal commitment is £100m in equity capital." Further details of the financing lined up by Mr Efune's consortium remain unclear, including the level of debt attached to his prospective offer. The RedBird-led acquisition of the Telegraph remains subject to investigations by both Ofcom and the Competition and Markets Authority, which are likely to delay completion of the deal into next year. Sky News previously revealed that Sir Leonard Blavatnik, owner of the DAZN sports streaming platform, and Daily Mail proprietor Lord Rothermere were preparing to buy minority stakes as part of the RedBird transaction. Gerry Cardinale, the RedBird executive, who has spearheaded the latest iteration of its acquisition, has described the firm as "the right owner at the right time". RedBird said in May that it was "in discussions with select UK-based minority investors with print media expertise and strong commitment to upholding the editorial values of the Telegraph". The Telegraph titles' parent company was forced into insolvency proceedings in 2023 by Lloyds Banking Group, which ran out of patience with the Barclay family, their long-standing owner. RedBird IMI, a joint venture between the two firms, paid £600m several months later to acquire a call option that was intended to convert into ownership of the Telegraph newspapers and The Spectator magazine. That objective was thwarted by a change in media ownership laws - which banned any form of foreign state ownership. Some peers argued last week that a 15% threshold was too high and that the legislation to permit it was dangerously ambiguous because it could allow for more than one state investor to aggregate their holdings in British newspapers. A further statutory instrument will need to be approved in order to address this issue. The Spectator, which had also been part of the same group, was sold last year for £100m to Sir Paul Marshall, the hedge fund billionaire, who has installed Lord Gove, the former cabinet minister, as its editor.
Skift
5 hours ago
- Skift
MakeMyTrip Expands International Listings with Premier Inn's 900+ European Hotels
As direct competition in India is increasing and suppliers are cutting middlemen, MakeMyTrip is moving to international markets to increase supply and distinguish itself. Online travel agency MakeMyTrip has partnered with UK-based hotel chain Premier Inn. Under the partnership, more than 900 Premier Inn properties across the UK, Germany and Ireland have been added to MakeMyTrip's international hotel portfolio. For Premier Inn, the partnership with MakeMyTrip will help increase awareness of the brand in India and neighboring countries. MakeMyTrip's decision was driven by the UK being one of the most preferred destinations for Indian travelers, said Rajesh Magow, co-founder and group CEO of MakeMyTrip. The partnership is a key part of the OTA's strategy to capitalize on India's outbound surge. International Strategy: This is MakeMyTrip's latest effort to expand its international hotel supply. The company has been using a direct contracting strategy to add more hotels to its portfolio, with a focus on high-demand outbound destinations. In a statement, the company said in the past year, it has added more than 2,000 directly contracted hotels across 50 cities in 20 countries. 'These 50 cities collectively account for more than half of India's outbound travel,' MakeMyTrip's statement read. 'Over the past twelve months, we have pursued a focused strategy to deepen our international accommodation offerings across key hubs, particularly in long haul markets such as the UK, Europe, and the U.S.,' said Magow. �
Yahoo
14 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
